The Parkinson’s disease Therapeutic market is experiencing steady growth, with a projected market size of USD 4.3 billion in 2024. This positive trend is expected to continue, with the market reaching an estimated by USD 6.7 billion 2034. This translates to a CAGR of 5.1% over the next decade.
Advancements in medical research and technology are leading to more effective treatments. Innovations such as gene therapy stem cell research, and novel drug delivery systems are providing new hope for patients.
The rise in awareness and early diagnosis of Parkinson’s disease is contributing to market expansion. Improved diagnostic techniques, including advanced imaging technologies and biomarkers, enable earlier intervention, enhancing treatment efficacy and patient outcomes.
Increased investment in research and development by pharmaceutical companies and governmental bodies is fostering innovation. Partnerships between biotech firms and research institutions are accelerating the discovery of new drugs and therapies. The approval of new drugs and therapies by regulatory bodies, such as the FDA, is providing more options for patients and driving market growth.
The adoption of digital health technologies, including wearable devices and telemedicine, is improving disease management and patient adherence to treatment regimens, further propelling the market forward.
| Attributes | Details |
|---|---|
| Parkinson’s Disease Therapeutic Market Size (2024E) | USD 4.3 billion |
| Parkinson’s Disease Therapeutic Market Projected Size (2034F) | USD 6.7 billion |
| Value CAGR (2024 to 2034) | 5.1% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The Parkinson’s disease Therapeutic Market is witnessing robust growth, propelled by numerous key drivers and emerging opportunities. A significant driver is the increasing prevalence of Parkinson’s disease (PD) globally. With rising awareness and better diagnostic tools, more cases are being identified at earlier stages, prompting higher demand for therapeutic interventions.
A notable driver is the diversification of treatment options. Beyond traditional medications like Levodopa, there are a surge in the development of advanced therapies, including dopamine agonists, MAO-B inhibitors, and deep brain stimulation (DBS). The varied treatment modalities cater to different stages and severities of the disease, enhancing patient outcomes and expanding the market.
The pharmaceutical industry’s strategic shift towards developing disease-modifying treatments, rather than merely symptomatic relief, is also a significant market driver. Such treatments aim to slow down or halt disease progression, offering long-term benefits and attracting investment from both public and private sectors.
Biomarker research is opening new avenues for the market as well. Identifying biomarkers for early PD detection and monitoring treatment efficacy is crucial for personalized medicine. This precision approach not only improves patient care but also drives the demand for specialized therapeutic solutions.
The market is further boosted by the expanding role of artificial intelligence and machine learning in drug discovery and development. AI algorithms can analyze vast datasets to identify potential drug candidates, predict clinical trial outcomes, and streamline regulatory approval processes. This technological advancement accelerates the availability of new treatments and reduces development costs, thereby enhancing market growth.
Telemedicine and digital health platforms offer another burgeoning opportunity. These technologies facilitate remote monitoring and management of PD, improving access to care for patients in remote or underserved areas. Telehealth also supports continuous patient engagement, adherence to treatment plans, and timely interventions, thereby driving the adoption of PD therapeutic.
There is a growing trend of patient-centric care, emphasizing holistic management of PD. This approach includes not just pharmacological treatments but also physiotherapy, occupational therapy, speech therapy, and mental health support. Integrated care models enhance the overall quality of life for patients, thereby increasing the utilization of comprehensive therapeutic solutions.
Government initiatives and favorable regulatory frameworks play a crucial role in market expansion. Policies supporting research funding, faster drug approval processes, and subsidies for PD treatments encourage pharmaceutical companies to innovate and bring new products to market more swiftly.
The Parkinson’s disease Therapeutic Market is driven by a combination of increasing disease prevalence, diversified treatment options, advances in biomarker research, AI in drug development, telemedicine, patient-centric care, and supportive government policies. These factors collectively create a dynamic landscape with significant growth potential and opportunities for stakeholders in the healthcare industry.
The United States is predicted to hold the dominant market share in 2023 and is the fastest-growing market for Parkinson's disease during the forecast period.
The factors that lead to regional expansion involve very prevalent Parkinson's disease groups. The high prevalence found in the aging population fuels the growth of the Parkinson's disease market in the United States. In the United States, almost 1 billion people have Parkinson's disease.
According to Parkinson's Foundation figures, this amount is significantly more than the total number of persons diagnosed with multiple sclerosis as well as muscular dystrophy.
The overall direct and indirect expenses of Parkinson's disease, including treatment, social payments, and lost income, are estimated to be about USD 52 billion per year in the United States alone.
The Parkinson's Prevalence Project predicts that 930,000 persons in the United States will have Parkinson's disease (PD) by 2020. This figure is estimated to reach 1.2 Billion by the year 2030. Hence, there would be a lot of scope for the manufacturers in the United States to develop in this market during the forecast period.
During the forecast period, the market for Parkinson's disease in China is expected to grow at a healthy pace. The emergence of a larger number of generic manufacturers as well as substantial market prospects for Parkinson's disease, in China will eventually drive the geographical expansion of the Parkinson's disease market in China.
The country is also seeing growth as a result of expanded product penetration, untapped potential, and the rising prevalence of Parkinson's disease in emerging nations. For example, UCB S.A. got an Import Drug License (IDL) from the China Food and Drug Administration (CFDA) in July 2022 to supply and distribute Neupro in China.
Neupro is suggested as monotherapy in conjunction with levodopa for the treatment of people with early-stage idiopathic Parkinson's disease. Such developments are expected to accelerate the growth in the market during the forecast period.
In the United Kingdom, several key factors are driving the Parkinson’s disease Therapeutic Market. A primary factor is the robust funding and support from governmental and non-governmental organizations dedicated to Parkinson’s research and patient care.
The UK’s National Health Service (NHS) ensures widespread access to advanced treatments and specialist services, facilitating early diagnosis and comprehensive management of Parkinson’s disease.
Another driving factor is the UK's strong pharmaceutical and biotech sector, which is at the forefront of developing innovative therapies and conducting cutting-edge clinical trials. Collaborative efforts between universities, research institutions, and pharmaceutical companies enhance the pace of medical advancements.
Public awareness campaigns and support groups also play a crucial role, educating the public about Parkinson’s disease and promoting early intervention. The UK’s emphasis on precision medicine and personalized treatment plans further boosts the adoption of novel therapeutic, improving patient outcomes and driving market growth.
Principal Consultant
Over the course of the forecast period, the Carbidopa-levodopa segment by drug class is anticipated to occupy a significant share of the global Parkinson's disease market. In 2023, this category is anticipated to dominate with a revenue share.
The high incidence of these medications' prescriptions was thought to be the cause of this rise. According to the US Drug Use Statistics, 183,670 Parkinson's patients are expected to receive 527,540 prescriptions for carbidopa-levodopa in 2021.
Combinations of the drugs carbidopa along with levodopa are used to treat Parkinson's disease (PD) symptoms. It is the most effective drug for PD and is frequently used as a second line of therapy. It can be taken largely orally, for example, as immediate-release pills, controlled-release tablets, enteral solution, or extended-release capsules.
The existence of pipeline candidates like LY03003 and an increase in the market for dopamine agonists are elements that are anticipated to favorably contribute to segmental growth. Such factors are expected to accelerate the growth prospects for Parkinson's disease during the forecast period.
On the basis of the age type, the other dominant segment is the adult segment, which is expected to occupy a global market share of in 2023.
According to the journal article 'Monoamine Oxidase-B Inhibitors for the Treatment of Parkinson's disease: Past, Present, and Future' released in February 2022, there are an estimated 6.1 Billion people worldwide who have Parkinson's disease. The prevalence rises with age, reaching from 1% to 3% in people over 65.
UN research estimates that 727 billion people worldwide would be 65 years of age or older in 2020. In addition, it is anticipated that by 2050, there will be twice as many people worldwide who are 80 years of age or older.
According to figures released by the World Health Organization (WHO) in October 2021, 1 in 6 persons worldwide would be 60 years of age or older by the year 2030. It is projected that there will be a demographic change as the world's geriatric population rises. The rise in older adults is anticipated to accelerate market growth over the projected period.
The competitive landscape of the Parkinson’s disease Therapeutic Market is characterized by intense rivalry among major pharmaceutical companies, biotech firms, and emerging startups.
Key players like Pfizer, AbbVie, and GlaxoSmithKline are heavily investing in R&D to develop advanced treatments. Innovative startups are also making significant strides with cutting-edge technologies such as gene therapy and neurostimulation devices.
Strategic partnerships, mergers, and acquisitions are common as companies aim to expand their portfolios and market reach. The race to develop disease-modifying therapies and personalized medicine solutions further intensifies competition, driving continuous innovation and growth in the market.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
By drug class, the industry is divided into carbidopa-levodopa, dopamine agonists, mao-b inhibitors, COMT inhibitors, anticholinergics and others.
By distribution channel, the industry is divided into hospital pharmacy, retail pharmacy and online pharmacy.
By brand, the industry is divided into branded and generics.
By route of administration, the industry is divided into oral, injectable, intestinal infusion, subcutaneous and others.
As per region, the industry is divided into North America, Latin America, Western Europe, South Asia, East Asia, Eastern Europe and Middle East & Africa.
The Parkinson’s disease Therapeutic Market is valued at USD 4.3 billion for 2024.
The Parkinson’s disease Therapeutic Market valuation is expected to be USD 6.7 billion by 2034.
The value of CAGR for the Parkinson’s disease Therapeutic Market is estimated to be 5.1%.
The Carbidopa-levodopa segment would garner a significant market value share by 2024.
1. Executive Summary 2. Industry Introduction, including Taxonomy and Market Definition 3. Market Trends and Success Factors, including Macro-economic Factors, Market Dynamics, and Recent Industry Developments 4. Global Market Demand Analysis 2019 to 2023 and Forecast 2024 to 2034, including Historical Analysis and Future Projections 5. Pricing Analysis 6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034 6.1. Drug Class 6.2. Distribution Channel 6.3. Brand 6.4. Route of Administration 7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Drug Class 7.1. Carbidopa-levodopa 7.2. Dopamine Agonists 7.3. MAO-B Inhibitors 7.4. COMT Inhibitors 7.5. Anticholinergics 7.6. Others 8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Distribution Channel 8.1. Hospital Pharmacy 8.2. Retail Pharmacy 8.3. Online Pharmacy 9. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Brand 9.1. Branded 9.2. Generics 10. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Route of Administration 10.1. Oral 10.2. Injectable 10.3. Intestinal Infusion 10.4. Subcutaneous 10.5. Others 11. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Region 11.1. North America 11.2. Latin America 11.3. Western Europe 11.4. South Asia 11.5. East Asia 11.6. Eastern Europe 11.7. Middle East & Africa 12. North America Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 13. Latin America Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 14. Western Europe Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 15. South Asia Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 16. East Asia Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 17. Eastern Europe Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 18. Middle East & Africa Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 19. Sales Forecast 2024 to 2034 by Drug Class, Distribution Channel, Brand, and Route of Administration for 30 Countries 20. Competition Outlook, including Market Structure Analysis, Company Share Analysis by Key Players, and Competition Dashboard 21. Company Profile 21.1. Merck & Co., Inc. 21.2. Mylan N.V. 21.3. Teva Pharmaceutical Industries Ltd. 21.4. Sun Pharmaceutical Industries Ltd. 21.5. Cipla Ltd. 21.6. Dr. Reddy's Laboratories Ltd. 21.7. Apotex Inc. 21.8. Sawai Pharmaceutical Co., Ltd. 21.9. Novartis 21.10. Zydus Cadila 21.11. Intas Pharmaceuticals Ltd. 21.12. Torrent Pharmaceuticals Ltd. 21.13. Amneal Pharmaceuticals 21.14. Aurobindo Pharma Limited 21.15. Accord Healthcare Ltd.
Explore Healthcare Insights
View Reports
Parkinson’s disease Therapeutic Market
